Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis

Abstract Introduction This study aimed to evaluate the influence of background conventional synthetic disease-modifying antirheumatic drug (csDMARD) use on efficacy and safety of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with psori...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Atul Deodhar, Miroslawa Nowak, June Y. Ye, Tom Lehman, Subhashis Banerjee, Philip J. Mease
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Adis, Springer Healthcare 2025-07-01
Ráidu:	Rheumatology and Therapy
Fáttát:	Psoriatic arthritis Tyrosine kinase 2 TYK2 Monotherapy Deucravacitinib csDMARDs
Liŋkkat:	https://doi.org/10.1007/s40744-025-00776-4
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!